Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Primary Bone Marrow Diffuse Large B-cell Lymphoma Presenting as Transverse Myelitis 2018
2018 14-3-3 proteins reduce cell-to-cell transfer and propagation of pathogenic α-synuclein 2018
2017 Dysregulation of 14-3-3 proteins in neurodegenerative diseases with Lewy body or Alzheimer pathology 2017
2017 Disparate genes come together: Spatial and genetic screens point to disruptions in vesicle trafficking and mRNA metabolism in synucleinopathies 2017
2016 CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial. 2016
2016 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening 2016
2015 14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease 2015
2015 Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins 2015
2014 Reaping what you sow: Cross-seeding between aggregation-prone proteins in neurodegeneration 2014
2013 LRRK2 secretion in exosomes is regulated by 14-3-3 2013
2013 α-synuclein overexpression represses 14-3-3θ transcription 2013
2013 IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation. 2013
2013 Angiogenin in Parkinson Disease Models: Role of Akt Phosphorylation and Evaluation of AAV-Mediated Angiogenin Expression in MPTP Treated Mice 2013
2012 Functional analysis of VPS41-mediated neuroprotection in Caenorhabditis elegans and mammalian models of Parkinson's disease 2012
2011 14-3-3theta protects against neurotoxicity in a cellular parkinson's disease model through inhibition of the apoptotic factor Bax 2011
2011 A neuroprotective role for angiogenin in models of Parkinson's disease 2011
2011 Defects in very long chain fatty acid synthesis enhance alpha-synuclein toxicity in a yeast model of Parkinson's disease 2011
2010 Target validation: The Parkinson disease perspective 2010
2010 Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease 2010
2009 Targets for neuroprotection in Parkinson's disease 2009
2009 Racial differences in parkinson's disease medication use in the reasons for geographic and racial differences in stroke cohort: A cross-sectional study 2009
2008 Transcriptional dysregulation in a transgenic model of Parkinson disease 2008
2008 Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. 2008
2000 Truncated and full-length TrkB receptors regulate distinct modes of dendritic growth 2000
1999 Subcellular localization of full-length and truncated Trk receptor isoforms in polarized neurons and epithelial cells 1999

Chapter

Year Title Altmetric
2016 Neurodegenerative Disorders: Why Do We Need New Therapies?.  1-16. 2016
2011 Neuroprotective Therapies for Parkinson’s disease 2011

Principal Investigator On

  • 14-3-3 Phosphorylation in Parkinson’s Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2019 - 2024
  • Innate and Adaptive Immunity in Parkinson Disease - Core B: Clinical Research Core  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by RETROPHIN, INC. 2019 - 2022
  • Regulation of Alpha Synuclein Release and Toxicity by Rab27b  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2020
  • Regulation of Cellular Release of Proteins in Parkinson's Neurodegeneration  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2014 - 2020
  • Southeastern Medical Scientist Symposium  awarded by National Institute of General Medical Sciences/NIH/DHHS 2019 - 2020
  • Clinical Trial Readiness for SCA 1 and SCA3  awarded by THE METHODIST HOSPITAL RESEARCH INSTITUTE 2018 - 2019
  • Rab27b As A Potential Regulator of Alpha-Synuclein Spread  awarded by American Parkinson Disease Association 2018 - 2019
  • Rab27b as a Potential Regulator of Alpha-Synuclein Spread  awarded by American Parkinson Disease Association 2017 - 2019
  • 14-3-3 Phosphorylation as a Biomarker for Parkinson's Disease  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2015 - 2018
  • 14-3-3 Regulation of Beta-Amyloid Toxicity  awarded by ALZHEIMER'S OF CENTRAL ALABAMA 2016
  • Effects of 14-3-3s on Alpha-Synuclein Release and Toxicity  awarded by American Parkinson Disease Association 2014 - 2016
  • 14-3-3 Phosphorylation as a Biomarker for Parkinson's Disease  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2014 - 2015
  • Effects of 14-3-3s on Alpha-Synuclein Release and Toxicity  awarded by American Parkinson Disease Association 2013 - 2014
  • Role of 14-3-3 Proteins in Alpha-Synuclein-Induced Neurotoxicity  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2008 - 2013
  • 14-3-3s as Regulators of LRRK2 Toxicity  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2011 - 2013
  • Effects of Coenzyme Q10 in PSP, A Multicenter, Randomized, Placebo-Controlled, Double Blind Study  awarded by LAHEY CLINIC, INC. 2011 - 2013
  • Education And Training

  • Massachusetts General Hospital, Residency 2005
  • Massachusetts General Hospital, Postdoctoral Fellowship 2006
  • Full Name

  • Talene Yacoubian